Roivant Sciences
Tracked across 8 events · 77 articles · First seen May 23, 2025 · Last active May 28, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
NewsDesk Dashboard
Business
Impact: Roivant Sciences announced the expansion of its brepocitinib program and the failure of Immunovant's batoclimab Phase 3 studies, which could negatively impact its stock.
Apr 02, 2026 · 16 articles
Domestic
The United States — Ohio gubernatorial race between Democrat Amy Acton and Republican Vivek Ramaswamy is heavily influenced by the COVID-19 pandemic. Amy Acton, as United States — Ohio's public health director in 2020, issued…
Impact: Roivant Sciences is a biotechnology research company founded by Vivek Ramaswamy. Its subsidiary, Roivant Sciences, was involved in a patent settlement with Moderna related to COVID vaccines.
May 02, 2026 · 9 articles
Business
Impact: Organon & Co.'s acquisition of Roivant Sciences is cited as a factor influencing Organon & Co.'s debt reduction strategy, which allegedly led to the dividend decrease.
May 29, 2025 · 6 articles
Business
Impact: Organon & Co.'s acquisition of Roivant Sciences is cited as a reason for Organon & Co.'s debt reduction strategy, which allegedly led to a decrease in its quarterly dividend.
May 23, 2025 · 6 articles
Business
Impact: Organon & Co. acquired Roivant Sciences for $1.2 billion in October 2024, an acquisition that increased Organon's debt and was cited as a reason for the dividend cut.
May 31, 2025 · 21 articles
Business
Impact: Organon & Co.'s acquisition of Roivant Sciences is cited as a factor influencing Organon & Co.'s debt reduction strategy, which in turn affected its dividend policy.
May 30, 2025 · 6 articles
Business
Impact: Organon & Co.'s acquisition of Roivant Sciences is cited as a factor in Organon & Co.'s debt reduction strategy, which allegedly led to a significant dividend decrease.
May 29, 2025 · 6 articles
Business
Impact: Organon & Co.'s acquisition of Roivant Sciences Ltd. is cited as a reason for Organon & Co.'s shift in capital allocation priorities towards debt reduction, impacting its dividend payout.
May 23, 2025 · 7 articles
Organon & Co.
target
↔
Roivant Sciences
Roivant Sciences was acquired by Organon & Co. for $1.2 billion in October 2024.
Organon & Co.
acquirer
↔
Roivant Sciences
Organon & Co. acquired Roivant Sciences for $1.2 billion in October 2024, a tran
NEWSDESK
Track Roivant Sciences live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard